Supernus Pharmaceuticals, Inc. (SUPN): Total Assets
$1.45B
As of 2025-12-31
$1.43B
As of 2026-06-30
-5.2%
3-year compound annual growth
-0.7%
5-year compound annual growth
+22.6%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.45B | +6.2% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $1.37B | +7.1% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $1.28B | -25.0% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $1.70B | +0.8% | 2023-03-09, Balance as of period end |
| 2021-12-31 | $1.69B | +12.3% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $1.50B | +29.6% | 2022-04-13, Balance as of period end |
| 2019-12-31 | $1.16B | +18.7% | 2021-03-08, Balance as of period end |
| 2018-12-31 | $977.81M | +130.4% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $424.46M | +37.1% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $309.57M | +64.1% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $188.63M | +37.9% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $136.78M | +23.2% | 2017-01-20, Balance as of period end |
| 2013-12-31 | $111.00M | +18.1% | 2015-03-12, Balance as of period end |
| 2012-12-31 | $93.99M | +74.9% | 2014-03-21, Balance as of period end |
| 2011-12-31 | $53.73M | n/a | 2013-03-15, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.45B | +6.2% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $1.63B | +3.3% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $1.26B | -18.6% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $1.32B | -5.1% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $836.65M | -0.5% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $763.63M | +31.5% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.53B | +1.9% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $1.66B | -0.4% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $689.80M | +21.3% |
Compare SUPN, AMPH, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗